Vanda Pharmaceuticals Announces Presentations at DDW 2023

Rhea-AI Summary

Vanda Pharmaceuticals to participate in Digestive Disease Week 2023

Positive

• Vanda Pharmaceuticals Inc. will be presenting at Digestive Disease Week (DDW) 2023, showcasing their research on the role of Tenascin-X in idiopathic gastroparesis and the efficacy analysis of Tradipitant in idiopathic and diabetic gastroparesis. The presentations will be held on May 7, 2023, during the AGA Gastroparesis and Small Intestinal Dysmotility session.

Negative

• None.

WASHINGTON, May 4, 2023 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced participation at Digestive Disease Week (DDW) 2023, to be held in Chicago, IL and online from May 6-9, 2023.

The following will be presented:

May 7, 2023

Presentation Title: "THE ROLE OF TENASCIN-X IN IDIOPATHIC GASTROPARESIS: WGS ANALYSIS"
Poster Number: Su1618
Presenter: Dr. Sandra Paulina Smieszek, Head of Genetics
Session Type: Poster Session
Session Title: AGA Gastroparesis and Small Intestinal Dysmotility
Session Time: 12:30 PM to 1:30 PM CDT

Presentation Title: "POOLED EFFICACY ANALYSIS OF TRADIPITANT IN IDIOPATHIC AND DIABETIC GASTROPARESIS STUDY VP-VLY-686-3301 AND VP-VLY-686-2301"
Poster Number: Su1632
Presenter: Dr. Jesse L. Carlin, Clinical Project Lead
Session Type: Poster Session
Session Title: AGA Gastroparesis and Small Intestinal Dysmotility
Session Time: 12:30 PM to 1:30 PM CDT

Presentation Title: "EFFICACY ANALYSIS OF TRADIPITANT IN IDIOPATHIC AND DIABETIC GASTROPARESIS IN STUDY VP-VLY-686-3301"
Poster Number: Su1633
Presenter: Dr. Jesse L. Carlin, Clinical Project Lead
Session Type: Poster Session
Session Title: AGA Gastroparesis and Small Intestinal Dysmotility
Session Time: 12:30 PM to 1:30 PM CDT

Presentation Title: "A BASELINE SEVERITY INFLATION ANALYSIS IN STUDY VP-VLY-686-3301 OF TRADIPITANT IN GASTROPARESIS"
Poster Number: Su1634
Presenter: Dr. Jesse L. Carlin, Clinical Project Lead
Session Type: Poster Session
Session Title: AGA Gastroparesis and Small Intestinal Dysmotility
Session Time: 12:30 PM to 1:30 PM CDT

For more information on DDW 2023, please refer to https://ddw.org/.

About Vanda Pharmaceuticals Inc.

Vanda is a leading global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high unmet medical needs and improve the lives of patients. For more on Vanda Pharmaceuticals Inc., please visit www.vandapharma.com and follow us on Twitter @vandapharma.

Corporate Contact:
Kevin Moran
Senior Vice President, Chief Financial Officer and Treasurer 
Vanda Pharmaceuticals Inc.
202-734-3400
pr@vandapharma.com

Elizabeth Van Every
Head of Corporate Affairs
Vanda Pharmaceuticals Inc.
202-734-3400
pr@vandapharma.com 

View original content:https://www.prnewswire.com/news-releases/vanda-pharmaceuticals-announces-presentations-at-ddw-2023-301816683.html

SOURCE Vanda Pharmaceuticals Inc.

FAQ

What is Digestive Disease Week 2023?

Digestive Disease Week (DDW) 2023 is a conference focused on digestive diseases and disorders.

What will Vanda Pharmaceuticals present at DDW 2023?

Vanda Pharmaceuticals will present their research on the role of Tenascin-X in idiopathic gastroparesis and the efficacy analysis of Tradipitant in idiopathic and diabetic gastroparesis.

When will the presentations take place?

The presentations will be held on May 7, 2023.

What is the session title for the presentations?

The presentations will be part of the AGA Gastroparesis and Small Intestinal Dysmotility session.

Who are the presenters?

Dr. Sandra Paulina Smieszek will present on the role of Tenascin-X, and Dr. Jesse L. Carlin will present on the efficacy analysis of Tradipitant.

Where can I find more information about DDW 2023?

More information about DDW 2023 can be found at https://ddw.org/.